Exparel Injectable Product

DRUG5 trials

Conditions

Breast AugmentationBunionCoronary Artery DiseaseCoronary Artery StenosesMusculoskeletal DiseasesPain, PostoperativeSoft Tissue MassValve Regurgitation, Mitral

Phase 1

Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety, of EXPAREL Administered as Sciatic Nerve Block (In Popliteal Fossa), for Postsurgical Analgesia in Subjects Undergoing Bunionectomy

CompletedNCT04002089

Pacira Pharmaceuticals, IncBunion

Start: 2019-07-26End: 2019-12-02Updated: 2021-01-11

Study to Evaluate the Pharmacokinetics and Safety of EXPAREL Administered as a Pectoral Plane Block in Women Undergoing Breast Augmentation

CompletedNCT04293809

Pacira Pharmaceuticals, IncBreast Augmentation

Start: 2019-12-19End: 2020-01-29Updated: 2024-01-29

Phase 2

The Efficacy of Exparel Versus a Multidrug Cocktail in Soft Tissue Tumors

TerminatedNCT05355597

Atlantic Health SystemMusculoskeletal Diseases, Soft Tissue Mass

Start: 2021-01-27End: 2025-03-24Updated: 2025-04-09

Phase 3

Comparison of Sternal Wound Infiltration With Liposomal Bupivacaine v. Bupivacaine Hydrochloride

CompletedNCT03270514

Kathirvel SubramaniamCoronary Artery Disease, Coronary Artery Stenoses, Valve Regurgitation, Mitral +1

Start: 2018-11-15End: 2020-02-25Updated: 2021-09-05

Phase 4

Modified TAP (Transverse Abdominis Plane) Block in Colorectal Surgery

CompletedNCT04781075

Ochsner Health SystemPain, Postoperative

Start: 2017-12-01End: 2021-07-31Updated: 2021-09-10

Related Papers

Liposomal Bupivacaine Transversus Abdominis Plane Blocks in Laparoscopic Colorectal Resections: A Single-Institution Randomized Controlled Trial

Diseases of the Colon & Rectum2022-05-248 citations